Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507377 | 0.97 | APP (0.47) | APPCYP2C19CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4503288 | 0.93 | OPRM1 (0.38) | APPCYP2C19CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4504736 | 0.91 | AKR1C3 (0.43) | APPCYP2C19CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4515335 | 0.87 | OPRM1 (0.41) | APPCYP2C19CYP2C9CYP3A4OPRM1 | |
| SCHEMBL4515775 | 0.86 | APP (0.46) | APPCYP2C19CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4503949 | 0.85 | OPRM1 (0.47) | APPCYP2C19CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4503379 | 0.84 | OPRM1 (0.51) | APPCYP2C19CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4517017 | 0.84 | AKR1C3 (0.43) | APPCYP2C19CYP2C9CYP3A4AKR1C3 | |
| SCHEMBL4495179 | 0.83 | CYP11B2 (0.43) | APPCYP2C19CYP2C9CYP2D6AKR1C3 | |
| SCHEMBL4491283 | 0.82 | FFAR4 (0.45) | APPCYP2C19CYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | claimed |
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | claimed |
| US-9056818-B2 | Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-16 | — | — | US | disclosed |
| US-20110039934-A1 | PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2- HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-02-17 | — | — | US | disclosed |
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | disclosed |
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039934-A1 | PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2- HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID | DHPS, CYP8B1, PCCA | APP 2816/4885CYP2C19 21/4885CYP2C9 5/4885 |
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MAOB, MAOA, XDH | APP 1024/4885CYP2C19 66/4885CYP2C9 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.